All‐cause mortality ‐ short term (end of treatment) · health problem or population
It is very uncertain whether summary of findings table ‐ Pharmacological treatment 1 changes all‐cause mortality ‐ short term (end of treatment) compared with pharmacological treatment 2 (very low certainty).
1 finding from 1 review
All‐cause mortality ‐ short term · health problem or population
It is very uncertain whether summary of findings table ‐ Pharmacological treatment changes all‐cause mortality ‐ short term compared with placebo (very low certainty).
1 finding from 1 review
All‐cause mortality · heart failure in patients with Chagas cardiomyopathy
It is very uncertain whether carvedilol changes all‐cause mortality compared with placebo (very low certainty).
1 finding from 1 review
All‐cause mortality · chronic heart failure in Chagas cardiomyopathy patients
1 finding from 1 review
All‐cause mortality · participants with high risk of sudden cardiac death (secondary prevention)
Amiodarone showed no clear difference in all‐cause mortality compared with other antiarrhythmics (low certainty).
1 finding from 1 review
All‐cause mortality · participants with high risk of sudden cardiac death (secondary prevention)
It is very uncertain whether amiodarone changes all‐cause mortality compared with beta blockers (very low certainty).
1 finding from 1 review
All‐cause mortality · participants with high risk of sudden cardiac death (secondary prevention)
It is very uncertain whether amiodarone changes all‐cause mortality compared with sotalol (very low certainty).
1 finding from 1 review
All‐cause mortality · participants with high risk of sudden cardiac death (primary prevention)
Amiodarone showed no clear difference in all‐cause mortality compared with placebo or no treatment (low certainty).
1 finding from 1 review
All‐cause mortality · beta blockers
Amiodarone may leads to lower all‐cause mortality compared with beta blockers (low certainty).
1 finding from 1 review
All‐cause mortality · participants with high risk of sudden cardiac death (primary prevention)
Amiodarone probably leads to lower all‐cause mortality compared with other antiarrhythmics (moderate certainty).
1 finding from 1 review
All‐cause mortality · participants with high risk of sudden cardiac death (secondary prevention)
It is very uncertain whether amiodarone changes all‐cause mortality compared with placebo or no treatment (very low certainty).
1 finding from 1 review
All‐cause mortality ‐ short‐term · health problem or population
It is very uncertain whether summary of findings table ‐ Psychological treatment changes all‐cause mortality ‐ short‐term compared with control (very low certainty).
1 finding from 1 review
All‐cause mortality ‐ short term (end of treatment) ‐ not reported · health problem or population
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found